Related Experiment Video

Updated: Aug 24, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Atypical pathogens and challenges in community-acquired pneumonia

Kristopher P Thibodeau1, Anthony J Viera

  • 1Naval Hospital Jacksonville, Jacksonville, Florida, USA. kthibodeau@sig.med.navy.mil

American Family Physician
|April 17, 2004
PubMed

Insights

Community-acquired pneumonia (CAP) treatment guidelines vary by patient age and setting. Empiric antibiotic therapy covers typical and atypical pathogens, with specific recommendations for outpatient, hospitalized, and intensive care unit (ICU) patients.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Atypical pathogens like Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila cause up to 40% of community-acquired pneumonia (CAP).
  • Current antibiotic treatment for CAP is empiric, aiming to cover both typical and atypical bacterial organisms.
  • Recognizing specific pathogens is crucial for effective CAP management.

Purpose of the Study:

  • To outline current antibiotic treatment strategies for community-acquired pneumonia (CAP).
  • To differentiate treatment recommendations based on patient demographics (adults vs. children) and clinical setting (outpatient, inpatient, ICU).
  • To address potential bioterrorism-related pulmonary illnesses and their management.

Main Methods:

  • Review of current clinical guidelines and literature on CAP treatment.
  • Analysis of antibiotic efficacy and spectrum of activity against common CAP pathogens.
  • Categorization of treatment regimens by patient population and severity of illness.

Main Results:

  • Outpatient treatment for immunocompetent adults: Doxycycline, a fluoroquinolone, or a macrolide.
  • Inpatient adult treatment: Cefotaxime or ceftriaxone plus a macrolide, or fluoroquinolone monotherapy.
  • Pediatric treatment varies: High-dose amoxicillin for young children, macrolides for older children, and macrolide plus beta-lactam for hospitalized children.
  • ICU adult treatment: Similar to inpatient, with alternatives like ampicillin-sulbactam or piperacillin-tazobactam.
  • Bioterrorism agents (anthrax, plague, tularemia) and Sudden Acute Respiratory Syndrome (SARS) present distinct clinical pictures.

Conclusions:

  • Antibiotic selection for CAP requires consideration of patient age, immune status, and clinical setting.
  • Specific regimens are recommended for typical and atypical pathogens in adults and children.
  • Awareness of bioterrorism-related respiratory illnesses and SARS is important for public health preparedness.

More Related Videos

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: